ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Epithelial SLC25A20 Deficiency Drives Immunosuppressive Neutrophil Remodeling via ARG1 Palmitoylation to Promote Colorectal Cancer.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
While lipid metabolic reprogramming is increasingly recognized as a substantial driver of tumor microenvironment (TME) remodeling, how dysregulated fatty acid oxidation (FAO) contributes to immune evasion in colorectal cancer (CRC) progression remains obscure. Here, we identify the mitochondrial carnitine-acylcarnitine translocase solute carrier 25 member 20 (SLC25A20), an essential conduit for FAO, as a key regulator of CRC progression through neutrophil phenotypic remodel. Mechanistically, SLC25A20 deficiency in CRC cells blunts mitochondrial long-chain fatty acid (LCFA) import and FAO, triggering the release of LCFAs into the TME. This lipid-rich niche not only vigorously recruits tumor-associated neutrophils (TANs), but intrinsically programs them toward an immunosuppressive phenotype. Specifically, tumor-derived LCFAs enforce arginase-1 (ARG1) protein stability in TANs via ZDHHC18-mediated palmitoylation. This distinct post-translational modification (PTM) is indispensable for TAN-mediated CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.